Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neuren Pharmaceuticals Limited operates within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This action is distributed to 1 distinct examiner and is located in 1 distinct art unit. This distribution reflects a focused approach to patenting within the biotechnology sector.
BRAUN, MADELINE E is the busiest examiner for this portfolio. This examiner is managing 1 pending office action. Because the portfolio has 1 distinct examiner and 1 pending office action, the current workload is entirely centralized. This indicates a narrow focus for the company's pending legal matters at the patent office. For the practitioner, this means that BRAUN, MADELINE E is the sole arbiter of the company's current pending claims. The presence of 1 distinct art unit further emphasizes the specialized nature of the technology under review. This centralized prosecution profile suggests that the company's immediate intellectual property goals are concentrated in a single area of pharmaceutical development.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546234 | TREATMENTS OF PRADER-WILLI SYNDROME | BRAUN, MADELINE E | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546234 | TREATMENTS OF PRADER-WILLI SYNDROME | BRAUN, MADELINE E | 34d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18546234 | TREATMENTS OF PRADER-WILLI SYNDROME | BRAUN, MADELINE E | 1624 | §103§112 | Final Rejection | 34d | Pending | Aug 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial